Evgen Pharma plc announces that Glen Clack, MD, FFPM will be joining the company as Chief Medical Officer effective from May 1, 2021. Dr. Clack has over 30 years' experience in oncology and translational medicine, and held various roles within AstraZeneca for almost 20 years. Dr. Clack has specialised in early phase oncology clinical development with an emphasis on a number of important cancers and has a wealth of experience in conducting and managing clinical trials. He has successfully provided strategic and operational leadership from Phase I through to regulatory submissions and commercialisation. He has been a lead member of study, clinical development and project teams on multiple trials. Glen is an Honorary Professor of Translational Medicine at the University of Sheffield and an MSc Module Tutor and Honorary Lecturer in Translational Science at the University of Manchester.